Nuvo says new data shows Pennsaid effective for osteoarthritis

By Elaine Rigoli

Tampa, Fla., March 2 - Nuvo Research, Inc. announced the publication of a research paper in the March 1 issue of the Journal of Rheumatology showing that Pennsaid was equivalent to oral diclofenac for osteoarthritis treatment.

The author, Tanveer E. Towheed, MD, associate professor of medicine at Queen's University, concluded that Pennsaid is an effective topical non-steroidal anti-inflammatory in patients with osteoarthritis of the knee.

Apart from minor localized skin reactions, Pennsaid was as safe as the vehicle-control placebo, according to a company news release.

"We are pleased to see the publication of this independent review, in which the author notes the high quality of our clinical trials and reaffirms the efficacy and safety of Pennsaid in the treatment of osteoarthritis," president and chief executive officer Henrich Guntermann said in a statement.

The objective of the paper was to review four randomized controlled trials evaluating Pennsaid treatment of patients with osteoarthritis of the knee.

As reported in the paper, Pennsaid treatment resulted in a significant difference in favor of Pennsaid for pain, stiffness, physical function and patient global assessment measured by the Western Ontario and McMaster Osteoarthritis Index.

Over the course of 12 weeks, Pennsaid was as effective as oral diclofenac, but was much better tolerated, the release said.

Pennsaid is approved for sale in Canada and several European countries.

Nuvo is a publicly traded pharmaceutical company with headquarters in Markham, Ont.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.